Your gift is 100% tax deductible
Español
PDFs by language
Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Chat live online
Select the Live Chat button at the bottom of the page
Call us at 1-800-227-2345
Available any time of day or night
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
Your gift enables us to support people with cancer and fund research breakthroughs.
The amount must be greater than or equal to $5
Your gift is 100% tax deductible
Researchers around the world are working to find better ways to prevent, detect, and treat breast cancer, and to improve the quality of life of patients and survivors.
Current guidance on preventing and treating breast cancer as well as what might cause it (among other things) has come mainly from information discovered from research studies. Research studies can range from studies done in the lab to clinical trials done with hundreds of thousands of people. Clinical trials are carefully controlled studies that can gather specific information about certain diseases as well as explore promising new treatments.
Clinical trials are one way to get the latest cancer treatments that are being investigated. Still, they are not right for everyone. If you would like to learn more about clinical trials that might be right for you, start by asking your doctor if your clinic or hospital conducts clinical trials, or see Clinical Trials to learn more.
Studies continue to look at how certain lifestyle factors, habits, and other environmental factors, as well as inherited gene changes, might affect breast cancer risk. Here are a few examples:
Researchers are looking for ways to help reduce breast cancer risk, especially for women who are at high risk. Here are some examples:
Breast cancer tissue is routinely tested for the biomarkers ER, PR, and HER2 to help make treatment decisions. A biomarker is any gene, protein, or other substance that can be measured in blood, tissues, or other body fluids. Some studies are looking at whether testing for other biomarkers, such as HER3, might also be helpful, but research on this is still in early phases.
Circulating tumor DNA (ctDNA) is DNA that is released into the bloodstream when cancer cells die. Identifying and testing the ctDNA in the blood for biomarkers is a rapidly growing area of study.
Some ways ctDNA might potentially be used in breast cancer include:
Newer types of tests are being developed for breast imaging. Some of these are already being used in certain situations, while others are still being studied. It will take time to see if they are as good as or better than those used today. Some of these tests include:
For more on these tests, see Newer and Experimental Breast Imaging Tests.
New kinds of treatments for breast cancer are always being studied. For example, in recent years, several new targeted drugs have been approved to treat breast cancer.
But more and better treatment options are needed, especially for cancers like triple-negative breast cancer, where chemotherapy is the main option.
Some areas of research involving breast cancer treatment include:
Supportive care helps patients and caregivers manage the symptoms of cancer and side effects of cancer treatment. Clinical trials are looking at different medicines and techniques to try to improve supportive care for people with breast cancer. For example, some studies are investigating:
The American Cancer Society medical and editorial content team
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as editors and translators with extensive experience in medical writing.
Chan JCH, Chow JCH, Ho CHM, Tsui TYM, Cho WC. Clinical application of circulating tumor DNA in breast cancer. J Cancer Res Clin Oncol. 2021;147(5):1431-1442. doi:10.1007/s00432-021-03588-5.
Cullinane C, Fleming C, O’Leary DP, et al. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020;3(11):e2026921. doi:10.1001/jamanetworkopen.2020.26921.
Cuzick, J et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. The Lancet. 2014;383 (9922):1041 - 1048.
Goss, P.E., et al., Exemestane for Breast-Cancer Prevention in Postmenopausal Women. New England Journal of Medicine, 2011. 364(25): p. 2381-2391.
Greene LR, Wilkinson D. The role of general nuclear medicine in breast cancer. J Med Radiat Sci. 2015;62(1):54-65.
Henry NL, Bedard PL, and DeMichele A. Standard and Genomic Tools for Decision Support in Breast Cancer Treatment. In Dizon DS, Pennel N, Rugo HS, Pickell LF, eds. 2017 American Society of Clinical Oncology Educational Book. 53rd Annual Meeting. 2017.
Ignatiadis M, Lee M, and Jeffrey SS. Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility. Clin Cancer Res; 21(21); 4786–800.
Litton JK, Burstein HJ, Turner NC. Molecular Testing in Breast Cancer. Am Soc Clin Oncol Educ Book. 2019 Jan;39:e1-e7. doi: 10.1200/EDBK_237715. Epub 2019 May 17.
Magbanua MJM, Swigart LB, Wu HT, et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann Oncol. 2021;32(2):229-239. doi:10.1016/j.annonc.2020.11.007.
Mayer IA, Dent R, Tan T, et al. Novel Targeted Agents and Immunotherapy in Breast Cancer. In Dizon DS, Pennel N, Rugo HS, Pickell LF, eds. 2017 American Society of Clinical Oncology Educational Book. 53rd Annual Meeting. 2017.
National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/clinical-trials/search. A Vaccine (Alpha-Lactalbumin) for the Treatment of Stage II-III Triple-Negative Breast Cancer. Accessed January 19, 2022.
National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/clinical-trials/search. Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer. Accessed August 15, 2019.
National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/clinical-trials/search. Donepezil Hydrochloride in Improving Memory Performance in Breast Cancer Survivors after Chemotherapy. Accessed August 15, 2019.
National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/clinical-trials/search. Ruxolitinib in Preventing Breast Cancer in Patients with High Risk and Precancerous Breast Lesions. Accessed August 15, 2019.
National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/clinical-trials/search. Testing the Addition of a Blood Pressure Medication, Carvedilol, to HER-2 Targeted Therapy for Metastatic Breast Cancer to Prevent Cardiac Toxicity. Accessed August 15, 2019.
National Institute of Environmental Health Sciences. Breast Cancer. Last reviewed November 15, 2021. Accessed January 19, 2022. https://www.niehs.nih.gov/health/topics/conditions/breast-cancer/index.cfm.
Rossi G, Mu Z, Rademaker AW, Austin LK, Strickland KS, Costa RLB et al. Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer. Clin Cancer Res. 2018 Feb 1;24(3):560-568.
Shoukry M, Broccard S, Kaplan J, Gabriel E. The Emerging Role of Circulating Tumor DNA in the Management of Breast Cancer. Cancers (Basel). 2021;13(15):3813. Published 2021 Jul 29. doi:10.3390/cancers13153813.
Solin LJ, Gray R, Baehner FL, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013;105:701-710.
Yu M, Bardia A, Aceto N et al. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science. 2014 Jul 11; 345(6193): 216–220.
Last Revised: February 15, 2024
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.
We fund research breakthroughs that save lives. Your year-end gift helps find new treatments for cancer.